M
Marker Therapeutics, Inc. (MRKR)
NCM – Real vaqt narxi. Valyuta: USD
1.44
-0.01 (-0.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.44
-0.01 (-0.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Marker Therapeutics, Inc., klinik bosqichdagi immuno-onkologiya kompaniyasi, Qo'shma Shtatlarda gematologik malignliklar va qattiq o'smalar uchun T-hujayrali immunoterapiyalarni ishlab chiqadi va tijoratlashtiradi. Kompaniyaning ko'p antigenli (MAR)-T hujayrali terapiya texnologiyasi o'simta bilan bog'liq antigenlarni tanib oladigan va bu maqsadlarni ifodalovchi o'simta hujayralarini o'ldiradigan muhandisliksiz o'simtaga xos T-hujayralarning selektiv kengayishiga asoslangan. U limfoma va oshqozon osti bezi saratoni davolash uchun 1-bosqich sinovlarida bo'lgan MT-601 va o'tkir miyeloid leykemiya va mielodisplastik sindromlarni davolash uchun 1-bosqich sinovlarida bo'lgan MT-401-OTS ni ishlab chiqadi. Kompaniya ilgari TapImmune, Inc. nomi bilan tanilgan va 2018 yil oktyabr oyida Marker Therapeutics, Inc. nomini o'zgartirgan. Marker Therapeutics, Inc. 1999 yilda tashkil etilgan va shtab-kvartirasi Xyuston, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director |
| Dr. Maria-Bernadette Madel Ph.D. | Director of Corporate Operations & External Communications |
| Dr. Robert Z. Florkiewicz Sr., Ph.D. | Senior Director of Molecular Biology & Virology |
| Mr. Edmund Cheung | Vice President of Human Resources |
| Ms. Elizabeth Donnelly | Director of Administration |
| Ms. Mary Newman Ph.D. | Head of Regulatory Affairs |
| Patricia Allison | Head of Clinical Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | 8-K | tm2613511d1_8k.htm |
| 2026-03-20 | DEF 14A | tm261499-3_def14a.htm |
| 2026-03-19 | 8-K | tm268941d1_8k.htm |
| 2026-03-18 | 10-K | mrkr-20251231x10k.htm |
| 2026-03-10 | PRE 14A | tm261499-1_pre14a.htm |
| 2026-02-09 | 8-K | tm265663d1_8k.htm |
| 2025-11-14 | 8-K | tm2530894d1_8k.htm |
| 2025-11-13 | 10-Q | mrkr-20250930x10q.htm |
| 2025-11-05 | 8-K | tm2530129d1_8k.htm |
| 2025-10-06 | 8-K | tm2527906d1_8k.htm |